Surprise, Skepticism And Scorn: Reaction To Rumored Haleon Interest In Sanofi CHC
Analysts share their thoughts on reports that Haleon is interested in acquiring Sanofi Consumer Healthcare to enhance its market leading position.
You may also be interested in...
Reviewing the news that Sanofi will exit the OTC market after setting up its Consumer Healthcare business to go it alone.
The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn.
Major Europe-based consumer health players Sanofi Bayer, Reckitt and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q4 2022 results over the coming weeks.